Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 535 Bellevue Ave #8, Oakland, CA 94610, USA
- Website
- minutia.co
- Founded
- 2021
- Employees
- 11-50
- Estimated annual revenue
- $1M-$10M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Biotechnology
- SIC code
- 87 Engineering & Management Services
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Grant awards
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Aleutian Therapeutics, Inc. | Los Angeles, CA | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Regenerative Medical Solutions Inc. | Park Ridge, IL | — |
| (A Development Stage Company) | — | 813990 Other Similar Organizations (except Business, Professional, Labor, and Political Organizations) |
| Endomimetics, Inc. | Birmingham, AL | — |
| Asymmetrex, LLC | Boston, MA | — |
About the company
Minutia Inc. is a minority-owned, woman-owned, and Black American-owned for-profit corporate entity registered in SAM.gov, specializing in advanced biotechnology research with a focus on developing innovative solutions for medical challenges, particularly in the field of diabetes treatment. The company's core competencies center on stem cell research, nanosensor technology, and developing cutting-edge therapeutic approaches for complex medical conditions. Registered since August 2020 with an active SAM.gov profile valid through May 2025, Minutia Inc. has positioned itself as a sophisticated research and development organization targeting critical medical research gaps.
The company has secured multiple significant federal grant awards from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), all targeting transformative research in type 1 diabetes treatment. Specifically, Minutia Inc. has been awarded grants focused on developing advanced stem cell-derived pancreatic islet cell technologies, including projects aimed at increasing the resilience of cell grafts and creating real-time intracellular monitoring systems. Their research involves developing genetically modified stem cell-derived islet cells more resistant to inflammatory stress and immune rejection, and leveraging proprietary nanosensor technology to enable non-invasive monitoring of implanted cell grafts. The grants, including R43DK138729, R43DK130034, and R44DK130034, demonstrate the company's sophisticated approach to addressing complex medical challenges, with a particular emphasis on innovative solutions for cell replacement therapy, inflammation detection, and potential functional cures for type 1 diabetes.
Quick answers
Is Minutia Inc. registered in SAM.gov?
Yes. Minutia Inc.'s SAM.gov registration is active through December 19, 2026.
What is Minutia Inc.'s CAGE code?
Minutia Inc.'s CAGE code is 8PAL9, and its Unique Entity ID (UEI) is X282EKTBJGL5.
What is Minutia Inc.'s most recent federal award?
Minutia Inc.'s most recent federal grant award is Monitoring and increasing resilience of stem cell derived pancreatic islet cell grafts (R43DK138729), from National Institute of Diabetes and Digestive and Kidney Diseases (NIH), on July 20, 2024.
On GovTribe
See Minutia Inc.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors